Logo image of VERU

VERU INC (VERU) Stock Fundamental Analysis

NASDAQ:VERU - US92536C1036 - Common Stock

3.62 USD
+0.02 (+0.56%)
Last: 8/25/2025, 11:32:55 AM
Fundamental Rating

3

VERU gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. VERU has a great financial health rating, but its profitability evaluates not so good. VERU does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VERU has reported negative net income.
In the past year VERU has reported a negative cash flow from operations.
In the past 5 years VERU reported 4 times negative net income.
In the past 5 years VERU always reported negative operating cash flow.
VERU Yearly Net Income VS EBIT VS OCF VS FCFVERU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

VERU has a worse Return On Assets (-96.59%) than 74.61% of its industry peers.
Looking at the Return On Equity, with a value of -144.48%, VERU is doing worse than 64.77% of the companies in the same industry.
Industry RankSector Rank
ROA -96.59%
ROE -144.48%
ROIC N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
VERU Yearly ROA, ROE, ROICVERU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

VERU has a better Gross Margin (39.70%) than 60.10% of its industry peers.
VERU's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for VERU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
VERU Yearly Profit, Operating, Gross MarginsVERU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

7

2. Health

2.1 Basic Checks

VERU does not have a ROIC to compare to the WACC, probably because it is not profitable.
VERU has more shares outstanding than it did 1 year ago.
VERU has less shares outstanding than it did 5 years ago.
VERU has a better debt/assets ratio than last year.
VERU Yearly Shares OutstandingVERU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VERU Yearly Total Debt VS Total AssetsVERU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -10.57, we must say that VERU is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VERU (-10.57) is worse than 68.91% of its industry peers.
There is no outstanding debt for VERU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.57
ROIC/WACCN/A
WACC9.96%
VERU Yearly LT Debt VS Equity VS FCFVERU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 4.47 indicates that VERU has no problem at all paying its short term obligations.
VERU has a better Current ratio (4.47) than 67.88% of its industry peers.
VERU has a Quick Ratio of 4.47. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.47, VERU is doing good in the industry, outperforming 68.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47
VERU Yearly Current Assets VS Current LiabilitesVERU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for VERU have decreased strongly by -229.41% in the last year.
The Revenue has been growing slightly by 3.62% in the past year.
The Revenue for VERU have been decreasing by -11.89% on average. This is quite bad
EPS 1Y (TTM)-229.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-614.29%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to decrease by -16.75% on average over the next years. This is quite bad
The Revenue is expected to grow by 57.70% on average over the next years. This is a very strong growth
EPS Next Y-468.29%
EPS Next 2Y-165.15%
EPS Next 3Y-99.36%
EPS Next 5Y-16.75%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y57.7%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VERU Yearly Revenue VS EstimatesVERU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2028 2029 2030 2031 100M 200M 300M 400M 500M
VERU Yearly EPS VS EstimatesVERU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERU. In the last year negative earnings were reported.
Also next year VERU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERU Price Earnings VS Forward Price EarningsVERU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERU Per share dataVERU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as VERU's earnings are expected to decrease with -99.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-165.15%
EPS Next 3Y-99.36%

More info and screens

0

5. Dividend

5.1 Amount

VERU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERU INC

NASDAQ:VERU (8/25/2025, 11:32:55 AM)

3.62

+0.02 (+0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)12-15 2025-12-15/amc
Inst Owners32.64%
Inst Owner Change-22.48%
Ins Owners10.7%
Ins Owner Change0%
Market Cap53.07M
Analysts82
Price Target21.68 (498.9%)
Short Float %N/A
Short Ratio6.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.55%
Min EPS beat(2)20.51%
Max EPS beat(2)22.6%
EPS beat(4)2
Avg EPS beat(4)-0.97%
Min EPS beat(4)-28.68%
Max EPS beat(4)22.6%
EPS beat(8)5
Avg EPS beat(8)8.3%
EPS beat(12)5
Avg EPS beat(12)-8.84%
EPS beat(16)8
Avg EPS beat(16)1.35%
Revenue beat(2)1
Avg Revenue beat(2)-8.34%
Min Revenue beat(2)-100%
Max Revenue beat(2)83.32%
Revenue beat(4)3
Avg Revenue beat(4)7.3%
Min Revenue beat(4)-100%
Max Revenue beat(4)83.32%
Revenue beat(8)4
Avg Revenue beat(8)-4.34%
Revenue beat(12)5
Avg Revenue beat(12)-17.01%
Revenue beat(16)7
Avg Revenue beat(16)-12.43%
PT rev (1m)672.73%
PT rev (3m)696.87%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-900%
EPS NY rev (1m)-804.35%
EPS NY rev (3m)-622.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.6
P/FCF N/A
P/OCF N/A
P/B 1.99
P/tB 2.69
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-1.97
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS1.01
BVpS1.82
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -96.59%
ROE -144.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.7%
FCFM N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.05%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z -10.57
F-Score4
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)217.76%
Cap/Depr(5y)171.53%
Cap/Sales(3y)2.29%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-229.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-614.29%
EPS Next Y-468.29%
EPS Next 2Y-165.15%
EPS Next 3Y-99.36%
EPS Next 5Y-16.75%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y57.7%
EBIT growth 1Y42.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y63.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.21%
OCF growth 3YN/A
OCF growth 5YN/A